Connecta Therapeutics

Biotechnology - Therapeutics and Diagnostics


CONNECTA Therapeutics is a clinical stage biotechnology company committed to developing new treatments for Central Nervous System (CNS) disorders without treatment options and helping to improve the quality of life of patients and families.


The company is currently focused on the clinical development of a new first-in-class molecule, CTH120, for the treatment of Fragile X Syndrome (FXS) and other neurodevelopmental disorders with no specific treatment CTH120 was designed after the study of more than 30 molecular and cellular targets for neuroplasticity.


The molecule has been proven, in in vitro and in vivo studies, to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders. CTH120 has also shown a good ADME and safety profile in the regulatory toxicology studies. CONNECTA is currently conducting a Phase I clinical trial to assess the safety and tolerability of CTH120 in healthy volunteers.




Contact person: Jordi Fàbrega Casadellà

Location: Torre I - 04A04